🇺🇸 FDA

Intelligence · Clinical Pipeline

Phase II Pipeline Programs

Proof-of-concept and dose-finding clinical programs in Phase II development.

Programs
7,238

Quick answer

NovaPharmaNews tracks 7,238 phase ii pharmaceutical pipeline programs from ClinicalTrials.gov. Proof-of-concept and dose-finding clinical programs in Phase II development.

Top sponsors

Page 46 of 151

  1. EDP-235

    ENANTA PHARMACEUTICALS INC

    COVID-19

    phase 2 small molecule completed

    3 trials

  2. EDP-305 1 mg

    ENANTA PHARMACEUTICALS INC

    Primary Biliary Cholangitis

    phase 2 small molecule completed

    1 trial

  3. EDP-305 1.5 mg

    ENANTA PHARMACEUTICALS INC

    Non-Alcoholic Steatohepatitis

    phase 2 small molecule terminated

    1 trial

  4. EDP-305 Dose 1

    ENANTA PHARMACEUTICALS INC

    Non-Alcoholic Steatohepatitis

    phase 2 small molecule completed

    1 trial

  5. EDP-323 Dose Regimen 1

    ENANTA PHARMACEUTICALS INC

    RSV Infection

    phase 2 small molecule completed

    1 trial

  6. EDP-420 / Duration of Treatment - 3 days

    ENANTA PHARMACEUTICALS INC

    Community Acquired Pneumonia

    phase 2 small molecule active

    1 trial

  7. EDP-938

    ENANTA PHARMACEUTICALS INC

    Respiratory Syncytial Virus (RSV)

    phase 2 small molecule completed

    2 trials

  8. EDP-938

    ENANTA PHARMACEUTICALS INC

    Respiratory Syncytial Virus Infections

    phase 2 small molecule terminated

    1 trial

  9. EDP-938

    ENANTA PHARMACEUTICALS INC

    Respiratory Syncytial Virus

    phase 2 small molecule completed

    1 trial

  10. EDP-938

    ENANTA PHARMACEUTICALS INC

    RSV Infection

    phase 2 small molecule completed

    6 trials

  11. EDP-938 Dose 1

    ENANTA PHARMACEUTICALS INC

    RSV Infection

    phase 2 small molecule completed

    1 trial

  12. EDP-938, EDP-938 Placebo tablets

    ENANTA PHARMACEUTICALS INC

    Respiratory syncytial virus (RSV)

    phase 2 small molecule active

    1 trial

  13. EFAVIRENZ

    The George Institute

    Type C Niemann-Pick Disease

    phase 2 small molecule active

    1 trial

  14. EG-70 (phase 1)

    Shanghai Antengene Corporation Limited

    Superficial Bladder Cancer

    phase 2 small molecule active

    1 trial

  15. EGF816, EGF816, LEE011, LEE011

    Novartis Pharmaceuticals

    Different types of advanced cancer

    phase 2 small molecule active

    1 trial

  16. EGF816, INC280, EGF816, GEFITINIB, INC280, EGF816

    Novartis Pharmaceuticals

    cMET-dependent malignancies

    phase 2 small molecule active

    1 trial

  17. EGFR Antibody

    The First People's Hospital of Lianyungang

    Nasopharyngeal Cancinoma (NPC)

    phase 2 small molecule active

    1 trial

  18. EGFR-TK Inhibitor

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Nonsmall Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  19. EIK1001

    Eikon Therapeutics

    NSCLC

    phase 2 small molecule active

    1 trial

  20. EIK1003 5mg Tablets, PREDNISONE , ABIRATERONE , EIK1003 20mg Tablets, PACLITAXEL

    Eikon Therapeutics

    Advance solid tumors

    phase 2 small molecule active

    1 trial

  21. EIK1004 20mg Tablets, EIK1004 5mg Tablets

    Eikon Therapeutics

    Advanced solid tumors

    phase 2 small molecule active

    1 trial

  22. EIK1004-001 (IMP1707-001)

    Eikon Therapeutics

    Advanced Solid Tumors

    phase 2 small molecule active

    1 trial

  23. EIK1005

    Eikon Therapeutics

    Advanced Solid Tumors

    phase 2 small molecule active

    1 trial

  24. EIK1005 10mg Tablets, EIK1005 50mg Tablets, PEMBROLIZUMAB , EIK1005 200mg Tablets

    Eikon Therapeutics

    Advanced Solid Tumors

    phase 2 small molecule active

    1 trial

  25. ELACESTRANT

    Fondazione Telethon ETS

    Patients with HR-positive, HER2-negative, non-metastatic node positive BC eligible for neoadjuvant treatment (clinical stage II-III)

    phase 2 small molecule active

    1 trial

  26. ELI-002 7P

    Elicio Therapeutics

    Pancreatic Ductal Adenocarcinoma

    phase 2 small molecule active

    1 trial

  27. ELIGARD 22,5 mg, poudre et solvant pour solution injectable

    The George Institute

    Intermediate risk prostate cancer

    phase 2 small molecule active

    1 trial

  28. ELRANATAMAB

    Pfizer Australia Pty Ltd

    Multiple myeloma

    phase 2 small molecule active

    1 trial

  29. ELX-02

    Eloxx Pharmaceuticals

    Alport Syndrome

    phase 2 small molecule completed

    1 trial

  30. ELX-02

    Eloxx Pharmaceuticals

    Cystic Fibrosis

    phase 2 small molecule completed

    2 trials

  31. ELX-02

    Eloxx Pharmaceuticals

    Genetic Disease

    phase 2 small molecule terminated

    2 trials

  32. EMB-001

    BRIGHT MINDS BIOSCIENCES INC.

    Cocaine Use Disorder

    phase 2 small molecule completed

    2 trials

  33. EMB-01

    Shanghai University of Traditional Chinese Medicine

    Neoplasms

    phase 2 small molecule active

    1 trial

  34. ENCORAFENIB , CETUXIMAB

    The George Institute

    Patients with BRAF V600E-mutant metastatic colorectal cancer (mCRC) who had received and responded to a BRAF inhibitor-based treatment.

    phase 2 small molecule active

    1 trial

  35. ENDORET-PRGF

    The George Institute

    glaucoma

    phase 2 small molecule active

    1 trial

  36. ENFORTUMAB VEDOTIN , mRNA-4157, Placebo to V940, KEYTRUDA 25 mg/mL concentrate for solution for infusion

    Merck Sharp and Dohme

    Muscle-invasive Urothelial Carcinoma

    phase 2 small molecule active

    1 trial

  37. ENMD-2076

    CASI Pharmaceuticals

    Triple Negative Breast Cancer

    phase 2 small molecule completed

    1 trial

  38. ENMD-2076

    CASI Pharmaceuticals

    Advanced Adult Hepatocellular Carcinoma

    phase 2 small molecule completed

    1 trial

  39. ENMD-2076

    CASI Pharmaceuticals

    Ovarian Cancer

    phase 2 small molecule completed

    1 trial

  40. ENTECAVIR , Placebo to VAY736 150 mg/1 mL Solution for injection in pre-filled syringe, TENOFOVIR DISOPROXIL , TENOFOVIR ALAFENAMIDE , -, VAY736

    Novartis Pharmaceuticals

    Diffuse cutaneous systemic sclerosis (dcSSc)

    phase 2 small molecule active

    1 trial

  41. ENTR-601-44

    Entrada Therapeutics

    Duchenne Muscular Dystrophy (DMD)

    phase 2 small molecule active

    1 trial

  42. ENTR-601-44, SODIUM CHLORIDE

    Entrada Therapeutics

    Duchenne Muscular Dystrophy

    phase 2 small molecule active

    1 trial

  43. ENTR-601-45

    Entrada Therapeutics

    Duchenne Muscular Dystrophy (DMD)

    phase 2 small molecule active

    1 trial

  44. EOF5

    Fudan University

    Gastric Cancer

    phase 2 small molecule completed

    1 trial

  45. EP-104GI

    EUPRAXIA PHARMACEUTICALS INC.

    Eosinophilic Esophagitis

    phase 2 small molecule active

    1 trial

  46. EP-104IAR 25 mg

    EUPRAXIA PHARMACEUTICALS INC.

    Osteoarthritis, Knee

    phase 2 small molecule completed

    1 trial

  47. EP0062, ORSERDU 86 mg film-coated tablets, ORSERDU 345 mg film-coated tablets

    Lacuna Pharma Pty Ltd

    Breast Cancer

    phase 2 small molecule active

    1 trial

  48. EPCORITAMAB, RITUXIMAB

    Daiichi Sankyo

    Hematological Malignancies

    phase 2 small molecule active

    1 trial

Frequently asked questions

How many Phase II pipeline programs are in the directory?

7,238 published programs match this development stage in our ClinicalTrials.gov index.

What defines this pipeline stage?

Phase and status reflect ClinicalTrials.gov registry fields at last sync. See our clinical trial phases reference for methodology.

Data attribution: Data sources · All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.